Coloplast stock trades at DKK 419.90 after 9M growth report

Published on 09/28/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock carries a 5% to 6% organic-growth outlook for fiscal 2025/26. JPMorgan set a DKK 377.00 target on September 9 after 9M EBIT of DKK 5.599 billion.

Pop-Art-Comic-Illustration einer lächelnden Pflegekraft mit medizinischen Pflegeprodukten — Coloplast A/S (DK0060448595) als Medizintechnik-Firma inspiriert diese farbenfrohe Pop-Art-Comic-Szene mit einer freundlichen Pflegekraft dargestellt, Illustration mit AI erstellt.

Coloplast stock (ISIN DK0060448595) was trading at DKK 419.90 on Nasdaq Copenhagen on September 28, 2026, up 0.55 percent from the previous close. The latest company report shows continued organic growth, but margin pressure and the Kerecis business remain central to the investment case.

Nine month growth stays intact

According to Globenewswire on August 18, 2026, Coloplast delivered 6 percent organic growth in Q3 2025/26, while EBIT rose 5 percent in constant currencies to DKK 1.929 billion. For the first nine months, reported revenue increased 3 percent and EBIT reached DKK 5.599 billion, giving investors a quantified contrast between operating growth and currency pressure.

The company kept its fiscal 2025/26 guidance at 5 percent to 6 percent organic revenue growth and 5 percent EBIT growth in constant currencies. Free cash flow represented 20 percent of sales in the first nine months, compared with 16 percent in the prior-year period.

Kerecis keeps margins under pressure

The Q3 EBIT margin was 26 percent, down from 28 percent a year earlier, according to Globenewswire. Biologics revenue fell 6 percent, and the segment posted a negative 5 percent margin before purchase price allocation amortization as reimbursement changes affected demand.

That split is important for the stock: Chronic Care and Urology supplied growth, while Biologics and Kerecis diluted group profitability. The report also included expected special items of DKK 3.1 billion for fiscal 2025/26, reflecting a DKK 3.0 billion Kerecis impairment.

JPMorgan sets a lower bar

On September 9, 2026, Marketscreener reported that JPMorgan downgraded Coloplast to underweight and set a DKK 377.00 price target. That target is 10.22 percent below the September 28 price, highlighting the gap between the current quotation and the bank's valuation view.

Investing.com lists November 3, 2026, as the next earnings date. The upcoming report will test whether the unchanged growth guidance can offset the margin drag from Biologics and Kerecis.

Coloplast stock remains below its yearly high

Coloplast stock was trading at DKK 419.90 on Nasdaq Copenhagen on September 28, 2026, with a session range of DKK 416.90 to DKK 423.80 and a 52-week range of DKK 369.70 to DKK 631.40. Market capitalization stood at DKK 94.6 billion, while volume reached 74,194 shares.